The Suboxone Litigation MDL 3092 absorbed 97 new complaints on March 18, all filed by Peiffer Wolf in a coordinated surge alleging dental decay and tooth loss from buprenorphine/naloxone film products. The Depo-Provera Litigation MDL 3140 (N.D. Fla., Judge M. Casey Rodgers) added 76 cases the same day, with OnderLaw LLC filing 40 and Nigh Goldenberg Raso Vaughn PLLC adding six, joined by Weitz & Luxenberg, Seeger Weiss, Simmons Hanly Conroy, and Morgan & Morgan. These twin pharmaceutical dockets now dominate early 2026 mass tort volume and signal aggressive bellwether positioning by elite plaintiffs' firms before any case management order has issued.
Johnson & Johnson's talc defense suffered a procedural win March 17 when a California state court judge vacated a $950 million verdict, finding insufficient proof to support the award — a ruling that arrives as MDL 2738 (D.N.J.) logged 12 new federal complaints March 18 from Robinson Calcagnie, Wagstaff Law Firm, and Napoli Shkolnik. The state court reversal does not affect federal MDL proceedings but underscores the bifurcated risk J&J faces across parallel state and federal dockets.
The GLP-1 Receptor Agonists Litigation MDL 3094 (E.D. Pa., Judge Karen Marston) added seven gastroparesis claims against Novo Nordisk and Eli Lilly on March 18, with Hammers Law Firm filing three and Nigh Goldenberg Raso Vaughn PLLC, Morgan & Morgan, and Seeger Weiss each adding single cases. The filings continue building the liability track separate from the obesity drug MDL's personal injury and consumer protection dockets as early discovery proceeds.
Generated by LexGenius Feed. Signals sourced from PACER federal court dockets, FDA/OpenFDA adverse event database, Federal Register, PubMed, and Google News.
